News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Announces AZILECT® (Rasagiline Tablets) Data to be Presented at the 2013 International Congress of Parkinson’s Disease and Movement Disorders



6/14/2013 7:06:21 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson’s Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society (MDS). These presentations affirm Teva’s ongoing commitment to Parkinson’s disease (PD) research and underscore the potential of AZILECT® as a treatment modality for PD.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES